Viking Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Viking Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.000.000.000.000.000.000.000.00
Cost of Revenue0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Operating Expenses
Research & Development344.96101.6463.8154.2344.9831.9323.5619.04
Selling, General & Administrative48.3949.2837.0216.1210.7010.739.137.12
Operating Expenses393.34150.92100.8370.3655.6842.66-32.6926.16
Operating Income-393.34-150.92-100.83-70.36-55.68-42.66-32.69-26.16
Other Income/Expense
Interest Income0.0040.9415.021.590.703.230.003.24
Interest Expense0.00-0.09-0.09-0.06-0.02-0.110.000.40
Other Income/Expense33.700.110.00-0.040.020.070.141.39
Income
Income Before Tax-359.64-109.96-85.81-68.87-54.99-39.50-25.78-22.06
Income Tax Expense0.000.00-29.09-22.09-17.46-12.720.000.00
Net Income-359.64-109.96-85.90-68.87-54.99-39.50-25.78-22.06
Net Income - Continuous Operations-359.64-109.96-85.90-68.87-54.990.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.000.00
EBITDA-393.34-150.58-114.60-70.06-55.39-42.39-24.76-21.66
EBIT0.00-150.92-114.98-70.36-55.68-42.66-25.78-21.66
Depreciation & Amortization0.000.350.290.290.300.000.000.00
Earnings Per Share
Basic EPS-3.00-1.00-1.00-1.00-1.00-1.00--
Diluted EPS-3.00-1.00-1.00-1.00-1.00-1.00--
Basic Shares Outstanding112.67109.0494.3576.8377.2072.6071.9657.58
Diluted Shares Outstanding112.67109.0494.3576.8377.2072.6071.6157.58